1.
Clin Transl Oncol
; 7(9): 412-3, 2005 Oct.
Artículo
en Inglés
| MEDLINE
| ID: mdl-16238977
RESUMEN
Prostate-specific antigen (PSA) is the most commonly used tumour marker for prostate cancer, both in screening and in follow-up. However, there are many false positive increases in the presence of other prostate diseases and, currently, there is no consensus regarding sensitivity and specificity of the PSA test, nor what constitutes the upper limit of normality. We report a case of a 67-year-old patient with metastatic prostate cancer who, with increased level of alkaline phosphatase and normal PSA, showed clinical and radiological evidence of progression of the disease.
Asunto(s)
Adenocarcinoma/sangre , Neoplasias Óseas/secundario , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/sangre , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/patología , Anciano , Antineoplásicos/uso terapéutico , Neoplasias Óseas/diagnóstico por imagen , Neoplasias Óseas/tratamiento farmacológico , Humanos , Masculino , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/patología , Cintigrafía , Resultado del Tratamiento
2.
Clin Transl Oncol
; 7(8): 358-60, 2005 Sep.
Artículo
en Inglés
| MEDLINE
| ID: mdl-16185606
3.
Clin Transl Oncol
; 7(2): 95, 2005 Mar.
Artículo
en Inglés
| MEDLINE
| ID: mdl-15899215